New Diabetes Pill Burns Fat, Preserves Muscle Mass

Millions of people managing diabetes and obesity may soon have a new treatment option that works completely differently from popular medications like Ozempic.

Researchers at Karolinska Institutet and Stockholm University have developed an experimental pill that lowers blood sugar and burns fat by activating metabolism in skeletal muscle. Unlike GLP-1 drugs that reduce hunger, this treatment leaves appetite unchanged while helping preserve muscle mass.

The approach addresses a major concern with current weight loss medications. Many patients taking GLP-1 drugs experience unwanted muscle loss alongside fat loss, which can affect overall health and longevity.

The new drug uses a specially engineered molecule called a β2 agonist. Scientists designed it to boost beneficial muscle activity without overstimulating the heart, a problem that has limited similar treatments in the past.

In animal studies, the treatment improved blood sugar control and body composition while avoiding side effects like appetite suppression, muscle loss, and digestive problems. The pill format also eliminates the need for injections.

Early human trials included 48 healthy volunteers and 25 people with type 2 diabetes. All participants tolerated the treatment well, with no serious safety concerns reported in this Phase I study.

"Our results point to a future where we can improve metabolic health without losing muscle mass," says Tore Bengtsson, professor at Stockholm University. "Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy."

Why This Inspires

This breakthrough matters because it offers genuine choice in how people manage their health. Some patients struggle with the appetite suppression effects of GLP-1 drugs or worry about losing muscle mass during treatment.

The new pill could work alone or alongside existing medications, giving doctors and patients more flexibility. Because it operates through a completely different biological pathway than GLP-1 drugs, combining the two might deliver even better results for some people.

Shane C. Wright, assistant professor at Karolinska Institutet, emphasizes the potential impact. "This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity," he says.

The research team is now preparing a larger Phase II clinical trial through Atrogi AB, the company developing the drug. This next phase will test whether the benefits seen in early studies translate to real-world improvements for people living with diabetes or obesity.

The findings appear in the journal Cell, backed by funding from the Swedish Research Council and the Novo Nordisk Foundation, among others.

For the more than 500 million people worldwide living with diabetes, this research opens a promising new chapter in treatment options.